EE9500034A - Oksalüülaminobensofuraan- ja -bensotienüülderivaadid, nende valmistamismeetod ja kasutamine - Google Patents

Oksalüülaminobensofuraan- ja -bensotienüülderivaadid, nende valmistamismeetod ja kasutamine

Info

Publication number
EE9500034A
EE9500034A EE9500034A EE9500034A EE9500034A EE 9500034 A EE9500034 A EE 9500034A EE 9500034 A EE9500034 A EE 9500034A EE 9500034 A EE9500034 A EE 9500034A EE 9500034 A EE9500034 A EE 9500034A
Authority
EE
Estonia
Prior art keywords
oxalylaminobenzofuran
preparation
derivatives
benzothienyl
inventive
Prior art date
Application number
EE9500034A
Other languages
English (en)
Estonian (et)
Inventor
Br�unlich Gabriele
Fischer Rdiger
Es-Sayed Mazen
Hanko Rudolf
Tudhope Stephen
Sturton Graham
S. Abram Trevor
J. Mcdonald-Gibson Wendy
F. Fitzgerald Mary
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9410891A external-priority patent/GB9410891D0/en
Priority claimed from GB9410863A external-priority patent/GB9410863D0/en
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of EE9500034A publication Critical patent/EE9500034A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Indole Compounds (AREA)
  • Materials For Photolithography (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Optical Record Carriers (AREA)
EE9500034A 1994-05-31 1995-05-30 Oksalüülaminobensofuraan- ja -bensotienüülderivaadid, nende valmistamismeetod ja kasutamine EE9500034A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9410891A GB9410891D0 (en) 1994-05-31 1994-05-31 Oxalylamino-benzofuran-and benzothienyl-derivatives
GB9410863A GB9410863D0 (en) 1994-05-31 1994-05-31 Heterocyclycarbonyl substituted oxalylamino-benzofurane derivatives

Publications (1)

Publication Number Publication Date
EE9500034A true EE9500034A (et) 1995-12-15

Family

ID=26304969

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9500034A EE9500034A (et) 1994-05-31 1995-05-30 Oksalüülaminobensofuraan- ja -bensotienüülderivaadid, nende valmistamismeetod ja kasutamine

Country Status (29)

Country Link
US (1) US5565488A (ro)
EP (1) EP0685474B1 (ro)
JP (1) JPH083154A (ro)
KR (1) KR950032163A (ro)
CN (1) CN1119187A (ro)
AT (1) ATE171172T1 (ro)
AU (1) AU695464B2 (ro)
BG (1) BG99680A (ro)
CA (1) CA2150301A1 (ro)
CO (1) CO4600675A1 (ro)
CZ (1) CZ140895A3 (ro)
DE (1) DE69504753T2 (ro)
DK (1) DK0685474T3 (ro)
EE (1) EE9500034A (ro)
ES (1) ES2124461T3 (ro)
FI (1) FI952612A (ro)
HR (1) HRP950288A2 (ro)
HU (1) HUT71597A (ro)
IL (1) IL113894A (ro)
LV (1) LV11467B (ro)
MA (1) MA23603A1 (ro)
MY (1) MY130580A (ro)
NO (1) NO952129L (ro)
NZ (1) NZ272217A (ro)
PL (1) PL308825A1 (ro)
RO (1) RO113642B1 (ro)
SK (1) SK72195A3 (ro)
TN (1) TNSN95061A1 (ro)
ZA (1) ZA954400B (ro)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9614718D0 (en) * 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
DE60026855T2 (de) 1999-08-21 2006-12-07 Altana Pharma Ag Synergistische kombination von roflumilast und salmeterol
JP2005518446A (ja) * 2002-02-22 2005-06-23 バイエル・フアーマシユーチカルズ・コーポレーシヨン 過剰増殖性障害の処置に有用な縮合三環式複素環
US7144885B2 (en) 2002-02-22 2006-12-05 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
BRPI0409229A (pt) 2003-04-01 2006-03-28 Applied Research Systems inibidores das fosfodiesterases na infertilidade
JP2006526606A (ja) * 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 治療薬としてのシクロアルキル及びヘテロシクロアルキル置換されるベンゾチオフェン
DE602004007268D1 (de) * 2003-06-05 2007-08-09 Warner Lambert Co CYCLOALKYLSULFANYL-SUBSTITUIERTE BENZOiBöTHIOPHENE ALS THERAPEUTISCHE MITTEL
BRPI0411092A (pt) * 2003-06-05 2006-07-18 Warner Lambert Co benzo[b]tiofenos substituìdos com 3-arilsulfanila e com 3-heteroarilsulfanila como agentes terapêuticos
MXPA05012894A (es) * 2003-06-05 2006-02-22 Warner Lambert Co Benzofuranos 3-sustituidos como agentes terapeuticos.
US20040259926A1 (en) * 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
EP1644360A1 (en) * 2003-06-05 2006-04-12 Warner-Lambert Company LLC 3-substituted indoles and derivatives thereof as therapeutic agents
EP1664011A4 (en) * 2003-09-02 2009-02-25 Merck & Co Inc OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA
CA2666469A1 (en) * 2006-09-01 2008-03-06 Bayer Healthcare Ag Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
ES2616051T3 (es) 2008-12-02 2017-06-09 Wave Life Sciences Japan, Inc. Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
JP5998326B2 (ja) 2009-07-06 2016-09-28 ウェイブ ライフ サイエンス リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 新規核酸プロドラッグおよびその使用方法
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US10428019B2 (en) 2010-09-24 2019-10-01 Wave Life Sciences Ltd. Chiral auxiliaries
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
EP3248982A1 (en) 2011-07-19 2017-11-29 Wave Life Sciences Ltd. Thiosulfonate reagents for the synthesis of functionalized nucleic acids
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
SG10201912897UA (en) 2014-01-16 2020-02-27 Wave Life Sciences Ltd Chiral design
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0146243A1 (en) 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
US5120742A (en) * 1984-02-27 1992-06-09 Merck & Co., Inc. 17 β-acyl-4-aza-5 α-androst-1-ene-3-ones as 5 α-reductase inhibitors
GB9200623D0 (en) * 1992-01-13 1992-03-11 Bayer Ag Benzofuranyl and thiophenyl-methylthio-alkanecarboxylic acid derivatives
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives

Also Published As

Publication number Publication date
CO4600675A1 (es) 1998-05-08
NO952129L (no) 1995-12-01
DE69504753T2 (de) 1999-02-04
LV11467A (lv) 1996-08-20
CZ140895A3 (en) 1995-12-13
CA2150301A1 (en) 1995-12-01
IL113894A0 (en) 1995-08-31
NO952129D0 (no) 1995-05-30
BG99680A (en) 1996-01-31
TNSN95061A1 (fr) 1996-02-06
IL113894A (en) 1999-06-20
JPH083154A (ja) 1996-01-09
KR950032163A (ko) 1995-12-20
EP0685474A1 (en) 1995-12-06
MY130580A (en) 2007-06-29
ATE171172T1 (de) 1998-10-15
RO113642B1 (ro) 1998-09-30
HRP950288A2 (en) 1997-08-31
AU2028695A (en) 1995-12-07
CN1119187A (zh) 1996-03-27
LV11467B (en) 1996-12-20
HUT71597A (en) 1996-01-29
HU9501569D0 (en) 1995-07-28
NZ272217A (en) 1997-02-24
FI952612A0 (fi) 1995-05-29
EP0685474B1 (en) 1998-09-16
MA23603A1 (fr) 1996-04-01
ZA954400B (en) 1996-01-24
SK72195A3 (en) 1995-12-06
FI952612A (fi) 1995-12-01
ES2124461T3 (es) 1999-02-01
PL308825A1 (en) 1995-12-11
DE69504753D1 (de) 1998-10-22
AU695464B2 (en) 1998-08-13
US5565488A (en) 1996-10-15
DK0685474T3 (da) 1999-06-14

Similar Documents

Publication Publication Date Title
EE9500034A (et) Oksalüülaminobensofuraan- ja -bensotienüülderivaadid, nende valmistamismeetod ja kasutamine
ATE175671T1 (de) Heterocyclylcarbonylsubstituierte benzofuranyl- und -thiophenylalkancarbonsäurederivate
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DE122011100040I2 (de) Zusammensetzung, verfahren und instrument zur potenzierung der antitumoraktivitat und zur behandlungvon tumoren.
DK0685475T3 (da) Amino-benzofuryl- og thienylderivater
FI953899A0 (fi) Substituoituja atsolonijohdannaisia Helicobacterin aiheuttamien sairauksien hoitamiseksi
DK0683170T3 (da) Glucopyranosidbenzothiophener
DE69612006D1 (de) Methode zur gefässerweiterung mit (1,5-inter)arylprostaglandinderivaten
ATE357914T1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
NO20003785D0 (no) Anvendelse av 2-amino-6-trifluormetoksy-benzotiazol for prevensjon eller terapi av cerebellum dysfunksjon
ECSP951455A (es) Derivados de oxalilamino- benzofurano y benzotienilo
DE69428127D1 (de) Schädlingsbekämpfungsmittel